{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:11:57Z","timestamp":1771661517021,"version":"3.50.1"},"reference-count":24,"publisher":"Medical Association of Nippon Medical School","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2021,12,25]]},"DOI":"10.1272\/jnms.jnms.2022_89-104","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T22:07:22Z","timestamp":1615241242000},"page":"533-539","source":"Crossref","is-referenced-by-count":5,"title":["Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019"],"prefix":"10.1272","volume":"88","author":[{"given":"Masayoshi","family":"Kondo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makihiko","family":"Nagano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Tagui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Takemoto Y, Tanaka S, Tanabe J, Nakamura Y, Kohama A, Shibata S. Studies on the effects of primary therapy for DIC following circulatory arrest. Am J Hematol. 1986 Apr;21 (4):377-82.","DOI":"10.1002\/ajh.2830210406"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Minakata D, Fujiwara SI, Ikeda T, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019 Feb;109 (2):141-6.","DOI":"10.1007\/s12185-018-02567-w"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hoffmann M, Schroeder S, Kleine-Weber H, Muller MA, Drosten C, Pohlmann S. Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. antimicrob agents chemother [Internet]. 2020 May 21;64 (6):e00754-20. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32312781","DOI":"10.1128\/AAC.00754-20"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jang S, Rhee JY. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Int J Infect Dis [Internet]. 2020 Jul;96:500-2. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32470602","DOI":"10.1016\/j.ijid.2020.05.072"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Doi K, Ikeda M, Hayase N, Moriya K, Morimura N. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care. 2020 Jul 3;24 (1):392.","DOI":"10.1186\/s13054-020-03078-z"},{"key":"6","unstructured":"6. Zhan WQ, Li MD, Xu M, Lu YB. Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report. Eur Rev Med Pharmacol Sci. 2020 Mar;24 (6):3385-9."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Taniguchi H, Ogawa F, Honzawa H, et al. Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan. Acute Med Surg [Internet]. 2020 Jan-Dec;7 (1):e509. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32313662","DOI":"10.1002\/ams2.509"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8 (5):518-26.","DOI":"10.1016\/S2213-2600(20)30121-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18 (5):1023-6.","DOI":"10.1111\/jth.14810"},{"key":"10","unstructured":"10. Saito S. Chushayaku haigouhenka de-ta kensaku 2009 [Datebase on injectable drugs 2009]: Yakujishinpousya Publishing; 2009. p. 1-199. Japanese."},{"key":"11","unstructured":"11. Fukushima H, Mori S. Chushayaku no haigouhenka [Incompatibilities of parenteral injections]: F Copint\uff65Fuji syoin Publishing; 2002. p. 1-3098. Japanese."},{"key":"12","unstructured":"12. Ishimoto K. Chusyayaku cyouzai kansa manyuaru 2018 [Injectable drug audit manual 2018]: Elsevier Japan Publishing; 2018. p. 1-719. Japanese."},{"key":"13","unstructured":"13. American Society of Health-System Pharmacists. Handbook on injectable drugs: American Society of Health-System Pharmacists, Maryland: 2017. p. 1-1280."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Committee for the development of Japanese guidelines for the management of Pain, Agitation, and Delirium in intensive care unit, Japanese Society of Intensive Care Medicine. Shuchu chiryo ryoiki niokeru itami\uff65fuon\uff65semmo kanri no genjo chosa (2019 nen) [Nationwide survey of Pain, Agitation, and Delirium management in Japanese intensive care setting, 2019]. Nippon Shuchu Chiryo Igakkai Zasshi [J Jpn Soc Intensive Care Med] [Internet]. 2020;27 (2):150-8. Available from: http:\/\/search.jamas.or.jp\/link\/ui\/U325230016 Japanese.","DOI":"10.3918\/jsicm.27_150"},{"key":"15","unstructured":"15. Abe S, Matsumoto S, Kobayashi G, et al. ICU niokeru chushayaku haigou henka hayamihyo no sakusei to sono yuyousei no kento [Preparation of quick reference table on incompatibilities of injections for use in the ICU and investigation of the usefulness of this table]. Iyakuhin Johogaku [Jpn J Drug Inform] [Internet]. 2012;14 (2):75-81. Available from: http:\/\/search.jamas.or.jp\/link\/ui\/2012336626 Japanese."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Thabit AK, Hamada Y, Nicolau DP. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm [Internet]. 2017 Jan 1;74 (1):e47-54. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28007721","DOI":"10.2146\/ajhp150762"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL. Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated y-site administration. Clin Ther [Internet]. 2018 Feb;40 (2):261-9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29290374","DOI":"10.1016\/j.clinthera.2017.12.007"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm. 1992 Jul;49 (7):1716-9.","DOI":"10.1093\/ajhp\/49.7.1716"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shekar K, Roberts JA, McDonald CI, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012 Oct 15;16 (5):R194.","DOI":"10.1186\/cc11679"},{"key":"20","unstructured":"20. Minister of Health, Labour and Welfare. Clinical management of patients with COVID-19: A guide for front-line healthcare workers (Version 2.1) [Internet]. 2020 Jul 3 [cited 2020 Sep 11]. Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000121431_00111.html"},{"key":"21","unstructured":"21. American Society of Health-SystemPharmacists (ASHP). ASHP's Interactive Handbook on INJECTABLE DRUGS [Internet]. 2020 [cited 2020 Mar 21]. Available from: https:\/\/www.interactivehandbook.com\/Authentication\/Authentication.aspx"},{"key":"22","unstructured":"22. Asahi Kasei Pharma Corporation. Iyakuhin intabyu fomu, nafamosutattomeshirusanen chushayo 100 mg [The interview form of nafamostat mesylate 5th edition]. 2018 Dec. Japanese."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takasu Y, Yoshida M, Shimizu K, Asahara K, Tange M, Uchida T. Prediction of the stability of octreotide in a mixed infusion. Chem Pharm Bull (Tokyo). 2014;62 (4):316-21.","DOI":"10.1248\/cpb.c13-00681"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kanji S, Lam J, Johanson C, et al. Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units. Crit Care Med [Internet]. 2010 Sep;38 (9):1890-8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20562698","DOI":"10.1097\/CCM.0b013e3181e8adcc"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/88\/6\/88_JNMS.2022_89-104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T04:03:51Z","timestamp":1641009831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/88\/6\/88_JNMS.2022_89-104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,25]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2022_89-104","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,25]]},"article-number":"JNMS.2022_89-104"}}